Metformin restores crizotinib sensitivity in crizotinib-resistant human lung cancer cells through inhibition of IGF1-R signaling pathway

AIM: Despite the impressive efficacy of crizotinib for the treatment of ALK-positive non-small cell lung cancer, patients invariably develop therapeutic resistance. Suppression of the IGF-1R signaling pathway may abrogate this acquired mechanism of drug resistance to crizotinib. Metformin, a widely...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Oncotarget
Egile Nagusiak: Li, Li, Wang, Yubo, Peng, Tao, Zhang, Kejun, Lin, Caiyu, Han, Rui, Lu, Conghua, He, Yong
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Impact Journals LLC 2016
Gaiak:
Research Paper
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5085167/
https://ncbi.nlm.nih.gov/pubmed/27144340
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.9120
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak